We are leading an oncology revolution that will redefine the approach to cancer. Thanks to precision medicine, we are transforming healthcare towards proactive, predictive and personalised medicine.

This revolutionary approach is based on understanding the underlying biology of diseases and integrates genomic, molecular and clinical data to optimise health outcomes and improve quality of life for patients.

After unlocking innovation with genuine milestones in areas such as genomics and digital pathology, with a forward-looking vision we are now taking on the challenge of continuing to spur the advancement and improvement of healthcare.

To do this, we partner with innovative businesses and public and private organisations to turn Health 4.0 into a reality for patients and medical professionals alike.

Since its release, the Oncotype DX® Breast Recurrence Score has transformed the approach to patients with early-stage invasive breast cancer with positive hormone receptors and negative HER2 with or without lymph node involvement (up to three nodes) by accurately identifying the majority of women who could be treated without chemotherapy and the minority for whom chemotherapy could save their lives 1-6.

Bibliografía: 1.Sparano et al. N Engl J Med. 2018. 2.Nitz et al, Breast Cancer Res Treat 2017 3. Stemmer npj Breast Cancer 2017 3:32 and 4. Petkov et al. npj Breast Cancer. 2016. 5.Roberts et al. Breast Cancer Res Treat. 2017 6.Kalinsky k et al. N Engl J Med. 2021